Blair William & Co. IL Buys 7,827 Shares of Prestige Consumer Healthcare Inc. $PBH

Blair William & Co. IL grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 7.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 113,941 shares of the company’s stock after acquiring an additional 7,827 shares during the quarter. Blair William & Co. IL owned 0.23% of Prestige Consumer Healthcare worth $9,098,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. KLP Kapitalforvaltning AS boosted its holdings in Prestige Consumer Healthcare by 2.8% in the second quarter. KLP Kapitalforvaltning AS now owns 18,500 shares of the company’s stock worth $1,477,000 after acquiring an additional 500 shares in the last quarter. DAVENPORT & Co LLC raised its stake in shares of Prestige Consumer Healthcare by 34.0% in the second quarter. DAVENPORT & Co LLC now owns 20,728 shares of the company’s stock worth $1,655,000 after purchasing an additional 5,264 shares during the last quarter. Trust Co. of Vermont raised its stake in shares of Prestige Consumer Healthcare by 7.7% in the second quarter. Trust Co. of Vermont now owns 9,825 shares of the company’s stock worth $785,000 after purchasing an additional 700 shares during the last quarter. Truist Financial Corp raised its stake in shares of Prestige Consumer Healthcare by 41.1% in the second quarter. Truist Financial Corp now owns 5,906 shares of the company’s stock worth $472,000 after purchasing an additional 1,721 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Prestige Consumer Healthcare in the second quarter worth about $220,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analysts Set New Price Targets

PBH has been the subject of several research analyst reports. Wall Street Zen cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective for the company in a research note on Wednesday, September 24th. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Canaccord Genuity Group reduced their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Hold” and a consensus price target of $94.80.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $60.91 on Friday. The stock’s fifty day moving average is $65.27 and its two-hundred day moving average is $76.14. The firm has a market capitalization of $3.00 billion, a P/E ratio of 14.30, a price-to-earnings-growth ratio of 1.93 and a beta of 0.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. Prestige Consumer Healthcare Inc. has a fifty-two week low of $60.77 and a fifty-two week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The business had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. During the same period last year, the company earned $0.90 EPS. The business’s revenue for the quarter was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.